Episurf Medical: 21’Q4 Review – US on the horizon - Redeye

Redeye argues that the lower-than-anticipated sales do not reflect the long-term case of Episurf and that its potential US market entry by H2 this year will be an important milestone for the company. We expect a slower market ramp-up than previously and adjust our estimates, which are now including the Patellofemoral system. Our Fair Value remains intact.

Länk till analysen i sin helhet: https://www.redeye.se/research/832808/episurf-medical-21q4-review-us-on-the-horizon?utm_source=finwire&utm_medium=RSS